PortfoliosLab logoPortfoliosLab logo
BOLT vs. LAZR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BOLT vs. LAZR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bolt Biotherapeutics, Inc. (BOLT) and Luminar Technologies, Inc. (LAZR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


BOLT

1D
-9.39%
1M
-8.50%
YTD
-15.33%
6M
-12.14%
1Y
-23.72%
3Y*
-48.55%
5Y*
-57.48%
10Y*

LAZR

1D
0.00%
1M
0.00%
YTD
0.00%
6M
-78.56%
1Y
-94.52%
3Y*
-87.69%
5Y*
-77.92%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

BOLT vs. LAZR - Yearly Performance Comparison


2026 (YTD)20252024202320222021
BOLT
Bolt Biotherapeutics, Inc.
-15.33%-48.91%-52.22%-13.85%-73.47%-84.76%
LAZR
Luminar Technologies, Inc.
0.00%-96.50%-89.36%-31.92%-70.73%-49.30%

Correlation

The correlation between BOLT and LAZR is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.15

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.18

Correlation (All Time)
Calculated using the full available price history since Feb 8, 2021

0.19

Fundamentals

EPS

BOLT:

-$5.26

LAZR:

-$3.95

PS Ratio

BOLT:

4.01

LAZR:

0.15

Total Revenue (TTM)

BOLT:

$6.50M

LAZR:

$75.75M

Gross Profit (TTM)

BOLT:

$4.98M

LAZR:

-$16.13M

EBITDA (TTM)

BOLT:

-$28.67M

LAZR:

-$161.26M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BOLT vs. LAZR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BOLT
BOLT Risk / Return Rank: 2626
Overall Rank
BOLT Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
BOLT Sortino Ratio Rank: 3030
Sortino Ratio Rank
BOLT Omega Ratio Rank: 3030
Omega Ratio Rank
BOLT Calmar Ratio Rank: 2222
Calmar Ratio Rank
BOLT Martin Ratio Rank: 2121
Martin Ratio Rank

LAZR
LAZR Risk / Return Rank: 1010
Overall Rank
LAZR Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
LAZR Sortino Ratio Rank: 1212
Sortino Ratio Rank
LAZR Omega Ratio Rank: 88
Omega Ratio Rank
LAZR Calmar Ratio Rank: 00
Calmar Ratio Rank
LAZR Martin Ratio Rank: 88
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BOLT vs. LAZR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bolt Biotherapeutics, Inc. (BOLT) and Luminar Technologies, Inc. (LAZR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BOLTLAZRDifference
Sharpe ratioReturn per unit of total volatility

+0.09

Sortino ratioReturn per unit of downside risk

+0.87

Omega ratioGain probability vs. loss probability

1.00

0.84

+0.16

Calmar ratioReturn relative to maximum drawdown

-0.53

-1.02

+0.49

Martin ratioReturn relative to average drawdown

-0.98

-1.39

+0.41

BOLT vs. LAZR - Sharpe Ratio Comparison

The current BOLT Sharpe Ratio is -0.33, which is comparable to the LAZR Sharpe Ratio of -0.41. The chart below compares the historical Sharpe Ratios of BOLT and LAZR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BOLTLAZRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.33

-0.41

+0.09

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.78

-0.60

-0.18

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.80

-0.53

-0.28

Drawdowns

BOLT vs. LAZR - Drawdown Comparison

The maximum BOLT drawdown since its inception was -99.51%, roughly equal to the maximum LAZR drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for BOLT and LAZR.


Loading charts...

Drawdown Indicators


BOLTLAZRDifference

Max Drawdown

Largest peak-to-trough decline

-99.51%

-99.97%

+0.46%

Max Drawdown (1Y)

Largest decline over 1 year

-44.85%

-95.02%

+50.17%

Max Drawdown (3Y)

Largest decline over 3 years

-88.36%

-99.85%

+11.49%

Max Drawdown (5Y)

Largest decline over 5 years

-98.95%

-99.95%

+1.00%

Current Drawdown

Current decline from peak

-99.42%

-99.97%

+0.55%

Average Drawdown

Average peak-to-trough decline

-90.05%

-62.79%

-27.26%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.24%

69.58%

-45.34%

Volatility

BOLT vs. LAZR - Volatility Comparison

Bolt Biotherapeutics, Inc. (BOLT) has a higher volatility of 21.79% compared to Luminar Technologies, Inc. (LAZR) at 0.00%. This indicates that BOLT's price experiences larger fluctuations and is considered to be riskier than LAZR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BOLTLAZRDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.79%

0.00%

+21.79%

Volatility (6M)

Calculated over the trailing 6-month period

55.33%

192.17%

-136.84%

Volatility (1Y)

Calculated over the trailing 1-year period

72.84%

234.16%

-161.32%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

74.10%

131.58%

-57.48%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

75.41%

115.83%

-40.42%

Dividends

BOLT vs. LAZR - Dividend Comparison

Neither BOLT nor LAZR has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

BOLT vs. LAZR - Financials Comparison

This section allows you to compare key financial metrics between Bolt Biotherapeutics, Inc. and Luminar Technologies, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M20222023202420252026
26.00K
18.75M
(BOLT) Total Revenue
(LAZR) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BOLT and LAZR have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BOLT has higher volatility (21.79%) compared to LAZR (0.00%). In terms of maximum drawdown, BOLT dropped -99.51% vs LAZR's -99.97%.

BOLT currently has the higher Sharpe Ratio (-0.33 vs -0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BOLT and LAZR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer